Bausch Health Companies Inc.

BHC

NYSE · Specialty & Generic Drugs

$8.18

At close - Nov 6, 4:00 PM EST - USD

Market Cap$3.06B

P/E-3.7x

52W High$9.04

Volume3M

VCP Research Verdict2026Q3

Leverage-Heavy Recovery Masks Negative Equity and Earnings Volatility

Bausch Health's recent quarters show revenue rebounding to roughly $2.9B in 2026Q3 with operating margin reaching 33.4%, suggesting operating scale may be improving faster than sales.

GrowthMixed

ProfitabilityModerate

ValuationAttractive

TechnicalsStrong

Explore valuation models

MARKET ACTION

BHC price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

BHC+13.45%

S&P 500 (^GSPC)+7.63%

1-Year Return

BHC+22.27%

S&P 500 (^GSPC)+9.69%

3-Year Return

BHC+9.80%

S&P 500 (^GSPC)+72.76%

5-Year Return

BHC-71.03%

S&P 500 (^GSPC)+59.87%

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis

Trailing P/E5Y Low

-3.7x

Forward P/E

1.7x

EV/EBITDA0th %ile

5.4x

FCF YieldCash Flow

59.8%

Valuation vs 5-Year History

Multiple Range

Metric

Current

5Y Median

Historical Range

Percentile

P/E

-3.7x

16.2x

0th· Low

EV/EBITDA

5.4x

10.9x

0th· Low

Price/FCF

1.7x

3.9x

0th· Low

Current Multiple

5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection

Bear$120.70+1375.6%

Base (Fair)$223.27+2629.5%

Bull$324.12+3862.3%

$120.70 Bear$223.27 Base$324.12 Bull

Current Market Price: $8.18

Trades at a 96.3% discount to Base DCF ($223.27)

Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend

Revenue FY25

$10.27B+6.7% YoY

Net income FY25

$157M+441.3% YoY

Free cash flow FY25

$1B-20.4% YoY

Operating margin FY25

21.3%+5.2 pts YoY

ROIC (FY25)8.1%

Avg ROIC 5Y4%

ROE (FY25)578.1%

Piotroski Score7 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate6/12 (50%)

Revenue Beat Rate7/12 (58%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q4 2026Latest Oct 28, 2026	$1.77+41.6% vs $1.25	$2.9B+6.0% vs $2.7B
Q3 2026 Jul 29, 2026	$1.26+31.3% vs $0.96	$2.8B+8.7% vs $2.6B
Q2 2026 Apr 29, 2026	$0.78-3.7% vs $0.81	$2.5B+4.3% vs $2.4B
Q1 2026 Feb 18, 2026	$1.08-10.7% vs $1.21	$2.8B+2.1% vs $2.7B

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

4 Stories

PRNewsWire·2d ago

Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026

LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).

Zacks Investment Research·3d ago

BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks

Bausch Health Companies Inc. BHC emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised its full-year guidance while outlining anticipated headwinds from Xifaxan pricing changes and inventory adjustments.

Zacks Investment Research·4d ago

Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?

Here is how Bausch Health (BHC) and Bausch + Lomb (BLCO) have performed compared to their sector so far this year.

Zacks Investment Research·Oct 29, 2026

BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises

Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.

Filtered for Bausch Health Companies Inc.More Headlines

Compare before deciding

Benchmark BHC against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Bausch Health Companies Inc. (BHC)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
BHCBausch Health Companies Inc.Current	$8.18	$3.06B	-3.70	6.66%	-7.57%	578.12%	—
PBHPrestige Consumer Healthcare Inc.	$42.98	$2.04B	13.19	-4.31%	13.29%	8.19%	—
PRGOPerrigo Company plc	$15.85	$2.19B	-1.25	-2.75%	-43.27%	-68.13%	7.26%
BLCOBausch + Lomb Corporation	$19.99	$7.14B	-65.09	6.47%	-2.05%	-1.71%	—
COOThe Cooper Companies, Inc.	$62.36	$12.16B	21.15	5.06%	13.46%	6.88%	—
ABTAbbott Laboratories	$109.93	$191.48B	40.64	5.67%	9.75%	9%	2.14%

Compare BHC vs Peers

Bausch Health Companies Inc. (BHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PBH

Most directly comparable listed peer for BHC.

Scale Benchmark

vs NVS

Larger-name benchmark to compare BHC against a more recognizable public peer.

Peer Set

Compare Top 5

vs PBH, PRGO, BLCO, COO

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

BHC SEC Filings & Documents

Bausch Health Companies Inc. (BHC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Oct 28, 2026·SEC

Material company update

Jul 29, 2026·SEC

Material company update

Jul 1, 2026·SEC

10-K Annual Reports

FY 2026

Feb 19, 2026·SEC

FY 2025

Feb 20, 2025·SEC

10-Q Quarterly Reports

FY 2026

Oct 29, 2026·SEC

FY 2026

Jul 30, 2026·SEC

FY 2025

Oct 30, 2025·SEC

Get notified when BHC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

BHC Frequently Asked Questions

Bausch Health Companies Inc. (BHC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Bausch Health Companies Inc.'s revenue?

Bausch Health Companies Inc. (BHC) reported $11.11B in revenue over the trailing twelve months. Revenue was $10.27B in fiscal year 2025. That is 15361% more than the $66.4M of fiscal year 1996.

How fast is Bausch Health Companies Inc. growing?

Bausch Health Companies Inc. (BHC) grew revenue by 10.8% over the trailing twelve months, compared with the twelve months before.

Is BHC profitable?

No. Bausch Health Companies Inc. (BHC) reported a net loss of $841.0M over the trailing twelve months.

Dividend & Returns

What is BHC's return on equity?

Bausch Health Companies Inc. (BHC) had a return on equity (ROE) of 578.1% in fiscal year 2025. That is well above the market's typical 10-15%.

What is Bausch Health Companies Inc.'s free cash flow?

Bausch Health Companies Inc. (BHC) generated $1.83B in free cash flow over the trailing twelve months.

What if you invested $1,000 in BHC back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q4 2026Latest

Oct 28, 2026

$1.77+41.6%

vs $1.25

$2.9B+6.0%

vs $2.7B

Q3 2026

Jul 29, 2026

$1.26+31.3%

vs $0.96

$2.8B+8.7%

vs $2.6B

Q2 2026

Apr 29, 2026

$0.78-3.7%

vs $0.81

$2.5B+4.3%

vs $2.4B

Q1 2026

Feb 18, 2026

$1.08-10.7%

vs $1.21

$2.8B+2.1%

vs $2.7B

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

BHCBausch Health Companies Inc.Current

$8.18

$3.06B

-3.70

6.66%

-7.57%

578.12%

—

PBHPrestige Consumer Healthcare Inc.

$42.98

$2.04B

13.19

-4.31%

13.29%

8.19%

—

PRGOPerrigo Company plc

$15.85

$2.19B

-1.25

-2.75%

-43.27%

-68.13%

7.26%

BLCOBausch + Lomb Corporation

$19.99

$7.14B

-65.09

6.47%

-2.05%

-1.71%

—

COOThe Cooper Companies, Inc.

$62.36

$12.16B

21.15

5.06%

13.46%

6.88%

—

ABTAbbott Laboratories

$109.93

$191.48B

40.64

5.67%

9.75%

2.14%